Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study: Results from the Targeted Agent and Profiling Utilization Registry Study
Apar K. Ganti, Michael Rothe, Pam K. Mangat, Elizabeth Garrett-Mayer, Elie G. Dib, Herbert L. Duvivier, Eugene R. Ahn, Deepti Behl, Hossein Borghaei, Ani S. Balmanoukian, Anu Gaba, Rui Li, Kwabena Osei-Boateng, Ramya Thota, Gina N. Grantham, Abigail Gregory, Susan Halabi, Richard L. Schilsky
Research output: Contribution to journal › Article › peer-review
12Scopus
citations
Fingerprint
Dive into the research topics of 'Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study: Results from the Targeted Agent and Profiling Utilization Registry Study'. Together they form a unique fingerprint.